Andrew J. Fromkin sold $7.4M of IMVT
director at Immunovant, Inc.. 221,951 shares at an average of $33.51, traded May 28, 2026, filed May 29, 2026.
Score components
- +15RoleDirector
- +25Trade size$7.4M at market
- +20Share of holdings soldSold 75% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001341896-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 28, 2026 | MOption exercise Common Stock | +31,668 | $4.99 | $158k | 131,400 | May 29, 2026 |
| May 28, 2026 | MOption exercise Common Stock | +71,492 | $7.94 | $568k | 202,892 | May 29, 2026 |
| May 28, 2026 | MOption exercise Common Stock | +77,181 | $8.43 | $651k | 280,073 | May 29, 2026 |
| May 28, 2026 | MOption exercise Common Stock | +16,260 | $14.70 | $239k | 296,333 | May 29, 2026 |
| May 28, 2026 | SOpen-market sale Common Stock | -11,483 | $32.64 | $375k | 284,850 | May 29, 2026 |
| May 28, 2026 | SOpen-market sale Common Stock | -210,468 | $33.56 | $7.1M | 74,382 | May 29, 2026 |
| May 28, 2026 | MOption exercise Stock Option (right to buy)derivative | -31,668 | $0.00 | $0 | 0 | May 29, 2026 |
| May 28, 2026 | MOption exercise Stock Option (right to buy)derivative | -71,492 | $0.00 | $0 | 0 | May 29, 2026 |
| May 28, 2026 | MOption exercise Stock Option (right to buy)derivative | -77,181 | $0.00 | $0 | 0 | May 29, 2026 |
| May 28, 2026 | MOption exercise Stock Option (right to buy)derivative | -16,260 | $0.00 | $0 | 0 | May 29, 2026 |
Related signals
Other insiders at Immunovant, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 16, 2026 | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $72k 2,241 shares | -1% | |
| Pro nowfree Oct 16, 2026 | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $122k 3,809 shares | -2% | |
| Pro nowfree Oct 16, 2026 | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $43k 1,327 shares | -1% | |
| 35Weak | Immunovant, Inc. | Eric Venker Chief Executive Officer | $120k 3,506 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $103k 2,846 shares | -2% | |
| 0Weak | Immunovant, Inc. | Atul Pande director | $65k 1,500 shares | -1% | |
| 39Weak | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $135k 3,056 shares | -1% | |
| 50Moderate | Immunovant, Inc. | Tiago Girao Chief Financial Officer | $263k 6,798 shares | -3% | |
| 2Weak | Immunovant, Inc. | Atul Pande director | $60k 1,500 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $111k 2,857 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.